Written by The Osteoarthritis Gene Therapy Market is emerging as a promising area within regenerative and advanced medicine as researchers explore therapies that can address the underlying mechanisms of osteoarthritis rather than only managing symptoms. According to WiseGuyReports, the market was valued at approximately USD 1 billion in 2025 and is projected to reach USD 3 billion by 2035, expanding at a CAGR of 9.5% during 2026–2035. The increasing prevalence of osteoarthritis, aging populations, advances in genetic research, and growing demand for personalized treatment approaches are key factors supporting market growth.
Technological developments in gene therapy are creating new opportunities for osteoarthritis treatment. The market includes viral vectors, non-viral vectors, CRISPR, and RNA interference, with researchers working toward more precise genetic interventions and improved therapeutic outcomes. Applications include cartilage regeneration, pain management, disease modification, and inflammation reduction. Intra-articular administration is particularly important because it enables targeted delivery to affected joints, while personalized medicine approaches are gaining attention as researchers seek to tailor therapies according to individual patient profiles.
North America is expected to maintain a leading position in the global market, supported by advanced healthcare infrastructure, substantial research and development investments, and increasing activity in gene therapy development. Europe is also positioned for continued expansion, while Asia-Pacific is expected to record strong growth as healthcare expenditure, patient awareness, and biotechnology capabilities increase. South America and the Middle East and Africa are expected to develop more gradually as healthcare access improves and innovative treatment options become increasingly available.
The competitive landscape includes Novartis, Xencor, MediGene, Bristol Myers Squibb, Roche, Gilead Sciences, GeneTx Biotherapeutics, Sangamo Therapeutics, Intellia Therapeutics, Amgen, Regeneron Pharmaceuticals, Astellas Pharma, and other participants. Strategic collaborations, clinical research, advanced gene-delivery technologies, and increased funding are expected to shape the future of the industry. Growing interest in regenerative medicine and disease-modifying therapies may further encourage companies and research institutions to develop targeted gene-based solutions, creating significant opportunities for innovation across the osteoarthritis treatment landscape.